Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With a PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer

This is a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of
niraparib alone and in combination with PD-1 inhibitors in participants with locally advanced
and metastatic non-small cell lung cancer (NSCLC). The study will consist of 2 stages. In
stage 1, participants from Cohorts 1 and 2 will receive niraparib plus PD-1 inhibitor;
pembrolizumab and participants from Cohort 3 will receive niraparib alone. In Stage 2,
participants from Cohorts 1A and 2A will receive niraparib plus the PD-1 inhibitor, TSR-042
(Dostarlimab).